Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below 200 Day Moving Average – What’s Next?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $12.73 and traded as low as $12.61. Enanta Pharmaceuticals shares last traded at $13.14, with a volume of 112,824 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ENTA. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Rodman & Renshaw began coverage on Enanta Pharmaceuticals in a research report on Thursday, March 26th. They issued a “buy” rating and a $20.00 target price for the company. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.29.

Enanta Pharmaceuticals Price Performance

The stock has a market capitalization of $381.32 million, a P/E ratio of -4.11 and a beta of 0.99. The company’s 50 day simple moving average is $13.44 and its two-hundred day simple moving average is $12.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. The company had revenue of $18.62 million during the quarter, compared to analysts’ expectations of $16.14 million. On average, research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENTA. Janus Henderson Group PLC increased its position in Enanta Pharmaceuticals by 91.6% in the 4th quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock valued at $58,761,000 after acquiring an additional 1,782,745 shares in the last quarter. Farallon Capital Management LLC grew its stake in shares of Enanta Pharmaceuticals by 30.6% during the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after purchasing an additional 650,000 shares during the last quarter. Krensavage Asset Management LLC increased its holdings in shares of Enanta Pharmaceuticals by 30.8% in the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock valued at $43,626,000 after purchasing an additional 651,946 shares in the last quarter. Millennium Management LLC raised its position in Enanta Pharmaceuticals by 50.2% in the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after purchasing an additional 449,945 shares during the last quarter. Finally, Marshall Wace LLP raised its position in Enanta Pharmaceuticals by 0.8% in the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock worth $6,482,000 after purchasing an additional 6,522 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.